Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
Top Cited Papers
Open Access
- 10 February 2012
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 379 (9814), 432-444
- https://doi.org/10.1016/s0140-6736(11)61625-5
Abstract
No abstract availableKeywords
Funding Information
- British Heart Foundation
- Cancer Research UK
- Medical Research Council
- BHF Centre of Research Excellence, Oxford (RE/08/04)
This publication has 38 references indexed in Scilit:
- Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient careBritish Journal of Cancer, 2011
- Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline featuresBreast Cancer Research and Treatment, 2010
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe Lancet Oncology, 2010
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancerBreast Cancer Research and Treatment, 2009
- Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93Breast Cancer Research and Treatment, 2008
- Weekly Paclitaxel in the Adjuvant Treatment of Breast CancerThe New England Journal of Medicine, 2008
- Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast CancerJAMA, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004